A significant and growing trend observed in pediatric sleep clinics nationwide is the widespread use of melatonin by children. While naturally derived and often perceived as a benign sleep aid, concerns are mounting among medical professionals regarding its frequency of use, particularly when administered without direct medical supervision. This rise in melatonin consumption is occurring alongside increased parental reliance on supplements like magnesium, for which evidence supporting sleep benefits in children remains limited.
The exact prevalence of melatonin use among children is difficult to pinpoint due to varying reporting mechanisms and the supplement’s over-the-counter availability. However, a 2022 study published in JAMA indicated a tripling of melatonin use in adults between 2005 and 2018, with a concurrent increase in dosage. This trend appears to be mirrored in the pediatric population, fueled by aggressive marketing campaigns for children’s melatonin products. Many parents, facing the challenges of establishing consistent sleep routines, may view melatonin as a convenient shortcut, a sentiment echoed in online reviews. One father, quoted in a Wall Street Journal article, admitted, "as parents my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed." This anecdotal evidence highlights a perceived need for immediate solutions to sleep disturbances, potentially at the expense of addressing underlying behavioral or environmental factors.
Escalating Usage and Alarming Trends
Data from various sources paint a picture of escalating melatonin consumption globally. A New York Times report in May 2020 noted an 87% increase in melatonin sales in the year prior to March 2020. Their survey of 933 parents with children under 18 revealed that over half had administered melatonin to their children at some point. More recent and concerning statistics emerge from Scandinavia, where there has been an almost 500% increase in melatonin prescriptions. In the United States, melatonin has become the most common cause of overdose in pediatric emergency rooms and a frequent reason for calls to poison control centers, underscoring the potential for misuse and accidental ingestion.
Understanding Melatonin: Function and Misconceptions
Melatonin is a hormone naturally produced by the pineal gland in the brain. It plays a dual role: as a chronobiotic agent, it regulates the body’s circadian rhythm or internal clock, and at higher doses, it can act as a hypnotic, inducing sleepiness. Crucially, while its chronobiotic effect is present in all individuals, its hypnotic effect is not universal and is dose-dependent. The natural surge in melatonin levels occurs one to three hours before sleep onset, signaling the body that it is time to wind down. This signal is known as the "dim light melatonin onset" (DLMO).
For children experiencing insomnia, particularly difficulty falling asleep, melatonin is often prescribed after their scheduled bedtime has passed, indicating their bodies are not yet biologically ready for sleep. This is where interventions like "bedtime fading," which aligns bedtime with the child’s natural sleep onset, can be effective. However, the doses used clinically, ranging from 0.5 mg to 10 mg or higher, significantly exceed the endogenous levels produced by the body. This discrepancy raises questions about the long-term impact of administering supra-physiological doses.
Effectiveness and Limitations of Melatonin in Pediatric Sleep Disorders
Research into the efficacy of melatonin for sleep problems in children, while growing, still presents a complex picture with notable limitations. Studies often involve small sample sizes and short follow-up periods. A significant factor contributing to this data gap is that melatonin is regulated as a dietary supplement by the FDA in the U.S., rather than as a pharmaceutical. This regulatory status means that large-scale, long-term clinical trials, typically funded by pharmaceutical companies for approved medications, are not as prevalent for melatonin.
Despite these limitations, available research suggests that melatonin can lead to a modest increase in sleep duration, primarily by reducing the time it takes for a child to fall asleep. However, it is not a panacea for sleep issues. The International Pediatric Sleep Association (IPSA) offers comprehensive resources, including parent guides and literature reviews, that provide valuable insights into melatonin use.
Specific Applications and Evidence
-
Chronic Sleep Onset Insomnia in Typically Developing Children: A 2023 meta-analysis by Edemann-Callesen, combining data from 419 children, indicated an approximate 30-minute increase in total sleep time, with about 18 minutes attributed to a reduction in sleep latency (the time taken to fall asleep). Notably, this study found no improvement in daytime functioning and observed an increase in adverse events in the treatment group compared to placebo. The 2025 IPSA position paper on melatonin for typically developing children provides important recommendations for this age group, emphasizing a cautious approach.
-
Autism Spectrum Disorder (ASD): Sleep disturbances are highly prevalent in children with ASD, manifesting as prolonged sleep onset, reduced nighttime sleep, and frequent awakenings. Some research suggests that children with ASD may have naturally lower or less variable melatonin secretion. Studies on melatonin in this population generally show improvements in sleep efficiency and total sleep time, rather than solely sleep latency. The benefits appear to be more pronounced in older children. However, the effectiveness can wane over time, and higher doses may yield better results. A 2017 trial of a time-released formulation, PedPRM, showed significant improvements in sleep onset and duration, though this medication is not currently approved by the FDA in the U.S. The 2024 IPSA recommendations for melatonin use in ASD highlight the importance of integrating it into a behavioral management plan.
-
Attention Deficit Hyperactivity Disorder (ADHD): Sleep problems are frequently comorbid with ADHD, with estimates suggesting up to 70% of children with ADHD experience sleep difficulties. These can include delayed sleep onset, altered sleep architecture, and daytime sleepiness. A 2024 review by Cortese noted two positive randomized controlled trials demonstrating melatonin’s benefit. A systematic review by Larsson in the same year reported a 30-minute decrease in sleep latency and improved sleep efficiency, but no impact on quality of life or daytime ADHD symptoms. While one small trial suggested melatonin could help children with ADHD on stimulants, this was based on chart review.
-
Delayed Sleep Phase Syndrome (DSPS): This disorder, common in adolescents, is characterized by a significant shift in the natural sleep period, making it difficult to fall asleep at socially acceptable times. Melatonin plays a more clearly defined role in managing DSPS. Administering small doses several hours before the desired sleep onset, in conjunction with light exposure management and behavioral strategies, can effectively shift sleep periods earlier. This application, involving the chronobiotic effect of melatonin, is considered to have the most robust evidence of benefit.
-
Neurodevelopmental Delay: Children with various forms of neurodevelopmental delay may experience significant insomnia. Melatonin can be helpful in some cases, although concerns exist about persistently elevated daytime melatonin levels and subsequent daytime sleepiness. A 2023 review by Edemann-Callesen, examining melatonin in a mixed group of conditions including intellectual disability, found a modest increase in total sleep time, primarily due to reduced sleep latency, with no significant improvements in subjective sleep or daytime function.
-
Blindness and Eczema: Children with blindness may have disrupted circadian rhythms due to the absence of light cues, leading to sleep disorders. While limited trials in adults have shown some benefit, data for children is scarce. Similarly, children with eczema, who often experience sleep disturbances due to itching and discomfort, may benefit from melatonin, as suggested by some recent research indicating potential low melatonin levels in this population.
Areas of Concern and Regulatory Oversight
Despite its widespread use, several concerns surround melatonin for children:
-
Theoretical Side Effects: The potential for persistently elevated daytime melatonin levels, leading to daytime sleepiness, remains a theoretical concern. The long-term effects of chronic melatonin use in developing children have not been as rigorously studied as those for pharmaceuticals. Dr. David Kennaway, an Australian physician, has raised concerns about the inadequacy of long-term safety data, noting that melatonin is not registered for use in children and has undergone less stringent safety testing.
-
Regulatory Gaps: As a dietary supplement, melatonin is subject to less stringent regulatory oversight by the FDA compared to prescription medications. This can lead to variability in product quality, purity, and accurate labeling. Misleading labeling, as observed in some liquid preparations where the stated dose differs significantly from the actual amount per dropperful, can contribute to incorrect dosing and potential overdoses.
-
Lack of Long-Term Safety Data: While a 2020 study following 80 children on a specific long-acting melatonin formulation for two years found no evidence of adverse effects on growth or sexual development, this remains one of the more comprehensive long-term safety studies. The call for more extensive long-term research persists.
Navigating Melatonin Use: Guidance for Parents and Physicians
For parents whose children are already taking melatonin, the immediate reaction should not be panic, as concrete evidence of significant harm is limited. However, open communication with a pediatrician is paramount. If melatonin was initiated without medical consultation, discussing its necessity and potential alternatives is crucial. For children on long-term melatonin, a gradual dose reduction or transitioning to "as-needed" use can be explored. Emphasis should always be placed on establishing and maintaining robust sleep hygiene practices, including consistent bedtime routines, limiting screen time before bed, and ensuring an appropriate sleep schedule. The IPSA guidelines recommend limiting melatonin use to 3-6 months and periodically attempting to discontinue it.
When melatonin is deemed appropriate by a healthcare provider, careful consideration of timing and dosage is essential. The effectiveness of melatonin is influenced by when it is administered relative to the child’s usual sleep schedule. A lower dose given a few hours before bedtime can be more effective than a higher dose given at bedtime. The 2025 IPSA guidelines provide age-based dosing recommendations, generally starting at 0.5 mg and titrating upwards. Resources like a melatonin dosing calculator can assist parents and physicians in selecting the safest and most effective dose.
Purchasing USP Verified preparations, which adhere to the quality standards set by the U.S. Pharmacopeial Convention, may offer an added layer of assurance regarding product quality and accuracy.
The Takeaway: A Tool, Not a Cure-All
The decision to use melatonin for a child’s sleep issues is often made after considerable deliberation and attempts at behavioral interventions. With limited FDA-approved insomnia medications for children, melatonin serves as a valuable tool for many families, particularly for those with specific conditions like autism, neurodevelopmental delays, or delayed sleep phase syndrome. However, it is critical to understand that melatonin is not a substitute for good sleep hygiene. It should be used in conjunction with a comprehensive approach that addresses behavioral, environmental, and scheduling factors contributing to sleep disturbances. The ultimate goal remains to help children achieve healthy sleep with minimal reliance on medication, a shared objective between parents and healthcare providers.
